Author response for 'Benefit of Insulin Glargine/Lixisenatide for Reducing Residual Hyperglycaemia in Japan: Post‐Hoc Analysis of the LixiLan JP‐O2 Trial'

Autor:	Katsumi Iizuka, Mike Baxter, Daisuke Yabe, Daisuke Watanabe
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty business.industry Internal medicine Post-hoc analysis Medicine business Residual Insulin Glargine / Lixisenatide
DOI:	10.1111/dom.14537/v2/response1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::228803a44750acbd74acd5f899e6dca1 https://doi.org/10.1111/dom.14537/v2/response1 Zobrazit plný text záznamu